JP2007530690A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007530690A5 JP2007530690A5 JP2007506284A JP2007506284A JP2007530690A5 JP 2007530690 A5 JP2007530690 A5 JP 2007530690A5 JP 2007506284 A JP2007506284 A JP 2007506284A JP 2007506284 A JP2007506284 A JP 2007506284A JP 2007530690 A5 JP2007530690 A5 JP 2007530690A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- phenyl
- triazole
- trifluoromethyl
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- -1 hydroxy, amino, carboxy Chemical group 0.000 claims 23
- 125000000217 alkyl group Chemical group 0.000 claims 20
- 125000001424 substituent group Chemical group 0.000 claims 18
- 229910052736 halogen Inorganic materials 0.000 claims 15
- 150000002367 halogens Chemical class 0.000 claims 15
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 15
- 125000001072 heteroaryl group Chemical group 0.000 claims 12
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 12
- 125000003545 alkoxy group Chemical group 0.000 claims 11
- ZUSWDTWYONAOPH-UHFFFAOYSA-N [2-(trifluoromethyl)phenyl]hydrazine;hydrochloride Chemical group [Cl-].[NH3+]NC1=CC=CC=C1C(F)(F)F ZUSWDTWYONAOPH-UHFFFAOYSA-N 0.000 claims 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 8
- 150000001875 compounds Chemical class 0.000 claims 7
- 125000003118 aryl group Chemical group 0.000 claims 6
- 229910052799 carbon Inorganic materials 0.000 claims 6
- 125000004432 carbon atom Chemical group C* 0.000 claims 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims 6
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 6
- 125000004201 2,4-dichlorophenyl group Chemical group [H]C1=C([H])C(*)=C(Cl)C([H])=C1Cl 0.000 claims 5
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 claims 5
- 125000000753 cycloalkyl group Chemical group 0.000 claims 5
- 229910052739 hydrogen Inorganic materials 0.000 claims 5
- 239000001257 hydrogen Substances 0.000 claims 5
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 4
- 125000001041 indolyl group Chemical group 0.000 claims 4
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 4
- 125000003226 pyrazolyl group Chemical group 0.000 claims 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 125000004414 alkyl thio group Chemical group 0.000 claims 3
- 125000001624 naphthyl group Chemical group 0.000 claims 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 239000000126 substance Substances 0.000 claims 3
- 125000004769 (C1-C4) alkylsulfonyl group Chemical group 0.000 claims 2
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 2
- 125000004429 atom Chemical group 0.000 claims 2
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims 2
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims 2
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims 2
- 125000002541 furyl group Chemical group 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- 125000002883 imidazolyl group Chemical group 0.000 claims 2
- 125000002950 monocyclic group Chemical group 0.000 claims 2
- 125000002971 oxazolyl group Chemical group 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 125000000335 thiazolyl group Chemical group 0.000 claims 2
- 125000001544 thienyl group Chemical group 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- NTNLPJLHGXIPQN-UHFFFAOYSA-N 1-methyl-4-[4-methyl-5-[2-(trifluoromethyl)phenyl]-1,2,4-triazol-3-yl]indole Chemical compound N=1N=C(C=2C=3C=CN(C)C=3C=CC=2)N(C)C=1C1=CC=CC=C1C(F)(F)F NTNLPJLHGXIPQN-UHFFFAOYSA-N 0.000 claims 1
- 102100036506 11-beta-hydroxysteroid dehydrogenase 1 Human genes 0.000 claims 1
- 101710186107 11-beta-hydroxysteroid dehydrogenase 1 Proteins 0.000 claims 1
- 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 claims 1
- HNZNQYMAJIIXRK-UHFFFAOYSA-N 3,5-bis(2,3-dichlorophenyl)-4-methyl-1,2,4-triazole Chemical compound CN1C(C=2C(=C(Cl)C=CC=2)Cl)=NN=C1C1=CC=CC(Cl)=C1Cl HNZNQYMAJIIXRK-UHFFFAOYSA-N 0.000 claims 1
- YSTNAQKFFUCUFF-UHFFFAOYSA-N 3,5-bis(2,4-dimethylphenyl)-4-methyl-1,2,4-triazole Chemical compound CC1=CC(C)=CC=C1C(N1C)=NN=C1C1=CC=C(C)C=C1C YSTNAQKFFUCUFF-UHFFFAOYSA-N 0.000 claims 1
- SKWYKJHAARIWNY-UHFFFAOYSA-N 3,5-bis(2-chlorophenyl)-4-methyl-1,2,4-triazole Chemical compound CN1C(C=2C(=CC=CC=2)Cl)=NN=C1C1=CC=CC=C1Cl SKWYKJHAARIWNY-UHFFFAOYSA-N 0.000 claims 1
- JHFZCCZCHICRJQ-UHFFFAOYSA-N 3-(1-methoxynaphthalen-2-yl)-4-methyl-5-[2-(trifluoromethyl)phenyl]-1,2,4-triazole Chemical compound C1=CC2=CC=CC=C2C(OC)=C1C(N1C)=NN=C1C1=CC=CC=C1C(F)(F)F JHFZCCZCHICRJQ-UHFFFAOYSA-N 0.000 claims 1
- SOPZURRJHOEIOK-UHFFFAOYSA-N 3-(2,3-dichlorophenyl)-4-methyl-5-(2-methylphenyl)-1,2,4-triazole Chemical compound CC1=CC=CC=C1C(N1C)=NN=C1C1=CC=CC(Cl)=C1Cl SOPZURRJHOEIOK-UHFFFAOYSA-N 0.000 claims 1
- YZFAQSSIHAAJRY-UHFFFAOYSA-N 3-(2,3-dichlorophenyl)-5-(2-methoxyphenyl)-4-methyl-1,2,4-triazole Chemical compound COC1=CC=CC=C1C(N1C)=NN=C1C1=CC=CC(Cl)=C1Cl YZFAQSSIHAAJRY-UHFFFAOYSA-N 0.000 claims 1
- OOZPYYLPXHCVTL-UHFFFAOYSA-N 3-(2,4-dichlorophenyl)-5-(2-ethylsulfanylphenyl)-4-methyl-1,2,4-triazole Chemical compound CCSC1=CC=CC=C1C(N1C)=NN=C1C1=CC=C(Cl)C=C1Cl OOZPYYLPXHCVTL-UHFFFAOYSA-N 0.000 claims 1
- CYPQHTJOGCYFOC-UHFFFAOYSA-N 3-(2,6-dichlorophenyl)-4-methyl-5-[2-(trifluoromethyl)phenyl]-1,2,4-triazole Chemical compound CN1C(C=2C(=CC=CC=2)C(F)(F)F)=NN=C1C1=C(Cl)C=CC=C1Cl CYPQHTJOGCYFOC-UHFFFAOYSA-N 0.000 claims 1
- LZSNOGCKVOHLDL-UHFFFAOYSA-N 3-(2-bromophenyl)-4-methyl-5-(2-methylphenyl)-1,2,4-triazole Chemical compound CC1=CC=CC=C1C(N1C)=NN=C1C1=CC=CC=C1Br LZSNOGCKVOHLDL-UHFFFAOYSA-N 0.000 claims 1
- MBOZUGMFGFMJRX-UHFFFAOYSA-N 3-(2-bromophenyl)-4-methyl-5-[2-(trifluoromethyl)phenyl]-1,2,4-triazole Chemical compound CN1C(C=2C(=CC=CC=2)Br)=NN=C1C1=CC=CC=C1C(F)(F)F MBOZUGMFGFMJRX-UHFFFAOYSA-N 0.000 claims 1
- DJHDWMXPENBKGA-UHFFFAOYSA-N 3-(2-bromophenyl)-5-(2-chlorophenyl)-4-methyl-1,2,4-triazole Chemical compound CN1C(C=2C(=CC=CC=2)Cl)=NN=C1C1=CC=CC=C1Br DJHDWMXPENBKGA-UHFFFAOYSA-N 0.000 claims 1
- QMPIIRBLTUIZOA-UHFFFAOYSA-N 3-(2-bromophenyl)-5-(2-methoxyphenyl)-4-methyl-1,2,4-triazole Chemical compound COC1=CC=CC=C1C(N1C)=NN=C1C1=CC=CC=C1Br QMPIIRBLTUIZOA-UHFFFAOYSA-N 0.000 claims 1
- RISKLUFTIJVKSQ-UHFFFAOYSA-N 3-(2-chloro-4-ethylsulfanylphenyl)-5-(2-fluorophenyl)-4-methyl-1,2,4-triazole Chemical compound ClC1=CC(SCC)=CC=C1C(N1C)=NN=C1C1=CC=CC=C1F RISKLUFTIJVKSQ-UHFFFAOYSA-N 0.000 claims 1
- IYJZNIQXCCQOQI-UHFFFAOYSA-N 3-(2-chloro-4-fluorophenyl)-5-(2-chlorophenyl)-4-methyl-1,2,4-triazole Chemical compound CN1C(C=2C(=CC=CC=2)Cl)=NN=C1C1=CC=C(F)C=C1Cl IYJZNIQXCCQOQI-UHFFFAOYSA-N 0.000 claims 1
- QNMPWTBJPOAEDR-UHFFFAOYSA-N 3-(2-chlorophenyl)-4-methyl-5-[2-(trifluoromethoxy)phenyl]-1,2,4-triazole Chemical compound CN1C(C=2C(=CC=CC=2)Cl)=NN=C1C1=CC=CC=C1OC(F)(F)F QNMPWTBJPOAEDR-UHFFFAOYSA-N 0.000 claims 1
- AGZNKNKKQJFMDU-UHFFFAOYSA-N 3-(2-chlorophenyl)-4-methyl-5-[2-(trifluoromethyl)phenyl]-1,2,4-triazole Chemical compound CN1C(C=2C(=CC=CC=2)Cl)=NN=C1C1=CC=CC=C1C(F)(F)F AGZNKNKKQJFMDU-UHFFFAOYSA-N 0.000 claims 1
- QEVDPEQVRDLTHF-UHFFFAOYSA-N 3-(2-chlorophenyl)-5-(2,3-dichlorophenyl)-4-methyl-1,2,4-triazole Chemical compound CN1C(C=2C(=CC=CC=2)Cl)=NN=C1C1=CC=CC(Cl)=C1Cl QEVDPEQVRDLTHF-UHFFFAOYSA-N 0.000 claims 1
- ZCFPMOQXMQWXEP-UHFFFAOYSA-N 3-(2-chlorophenyl)-5-[2-chloro-3-(trifluoromethyl)phenyl]-4-methyl-1,2,4-triazole Chemical compound CN1C(C=2C(=CC=CC=2)Cl)=NN=C1C1=CC=CC(C(F)(F)F)=C1Cl ZCFPMOQXMQWXEP-UHFFFAOYSA-N 0.000 claims 1
- VNNVZCOWLMLJSK-UHFFFAOYSA-N 3-(2-cyclopropylphenyl)-5-(2,4-dichlorophenyl)-4-methyl-1,2,4-triazole Chemical compound CN1C(C=2C(=CC(Cl)=CC=2)Cl)=NN=C1C1=CC=CC=C1C1CC1 VNNVZCOWLMLJSK-UHFFFAOYSA-N 0.000 claims 1
- HEXZJRBEVHEMHA-UHFFFAOYSA-N 3-(2-ethoxyphenyl)-4-methyl-5-[2-(trifluoromethyl)phenyl]-1,2,4-triazole Chemical compound CCOC1=CC=CC=C1C(N1C)=NN=C1C1=CC=CC=C1C(F)(F)F HEXZJRBEVHEMHA-UHFFFAOYSA-N 0.000 claims 1
- CHPFOFYMIRFOLW-UHFFFAOYSA-N 3-(2-methoxyphenyl)-4-methyl-5-[2-(trifluoromethyl)phenyl]-1,2,4-triazole Chemical compound COC1=CC=CC=C1C(N1C)=NN=C1C1=CC=CC=C1C(F)(F)F CHPFOFYMIRFOLW-UHFFFAOYSA-N 0.000 claims 1
- POYZNCSBPDZNDU-UHFFFAOYSA-N 3-(3-chloronaphthalen-2-yl)-4-methyl-5-[2-(trifluoromethyl)phenyl]-1,2,4-triazole Chemical compound N=1N=C(C=2C(=CC3=CC=CC=C3C=2)Cl)N(C)C=1C1=CC=CC=C1C(F)(F)F POYZNCSBPDZNDU-UHFFFAOYSA-N 0.000 claims 1
- FWDPOAPCQUFKJP-UHFFFAOYSA-N 3-(5-chloro-6-methoxynaphthalen-1-yl)-4-methyl-5-[2-(trifluoromethyl)phenyl]-1,2,4-triazole Chemical compound C=1C=CC2=C(Cl)C(OC)=CC=C2C=1C(N1C)=NN=C1C1=CC=CC=C1C(F)(F)F FWDPOAPCQUFKJP-UHFFFAOYSA-N 0.000 claims 1
- UHUOSJYWUHGRMS-UHFFFAOYSA-N 3-[2-(4-chlorophenoxy)phenyl]-4-methyl-5-[2-(trifluoromethyl)phenyl]-1,2,4-triazole Chemical compound CN1C(C=2C(=CC=CC=2)OC=2C=CC(Cl)=CC=2)=NN=C1C1=CC=CC=C1C(F)(F)F UHUOSJYWUHGRMS-UHFFFAOYSA-N 0.000 claims 1
- UUXYDXHRHCAPFP-UHFFFAOYSA-N 3-[2-(4-chlorophenyl)sulfanylphenyl]-4-methyl-5-[2-(trifluoromethyl)phenyl]-1,2,4-triazole Chemical compound CN1C(C=2C(=CC=CC=2)SC=2C=CC(Cl)=CC=2)=NN=C1C1=CC=CC=C1C(F)(F)F UUXYDXHRHCAPFP-UHFFFAOYSA-N 0.000 claims 1
- FTXYRYYOOWJDNF-UHFFFAOYSA-N 3-[2-(4-fluorophenoxy)phenyl]-4-methyl-5-[2-(trifluoromethyl)phenyl]-1,2,4-triazole Chemical compound CN1C(C=2C(=CC=CC=2)OC=2C=CC(F)=CC=2)=NN=C1C1=CC=CC=C1C(F)(F)F FTXYRYYOOWJDNF-UHFFFAOYSA-N 0.000 claims 1
- TYFFATWJXTWJOA-UHFFFAOYSA-N 3-[2-(difluoromethoxy)phenyl]-4-methyl-5-[2-(trifluoromethyl)phenyl]-1,2,4-triazole Chemical compound CN1C(C=2C(=CC=CC=2)OC(F)F)=NN=C1C1=CC=CC=C1C(F)(F)F TYFFATWJXTWJOA-UHFFFAOYSA-N 0.000 claims 1
- YTHVYFZAJHQZDM-UHFFFAOYSA-N 3-[4-(4-chlorophenoxy)phenyl]-4-methyl-5-[2-(trifluoromethyl)phenyl]-1,2,4-triazole Chemical compound CN1C(C=2C=CC(OC=3C=CC(Cl)=CC=3)=CC=2)=NN=C1C1=CC=CC=C1C(F)(F)F YTHVYFZAJHQZDM-UHFFFAOYSA-N 0.000 claims 1
- NZGFCTSUVFOUQD-UHFFFAOYSA-N 3-[4-chloro-5-(2-chlorophenyl)-1-methylpyrazol-3-yl]-4-methyl-5-[2-(trifluoromethyl)phenyl]-1,2,4-triazole Chemical compound CN1N=C(C=2N(C(C=3C(=CC=CC=3)C(F)(F)F)=NN=2)C)C(Cl)=C1C1=CC=CC=C1Cl NZGFCTSUVFOUQD-UHFFFAOYSA-N 0.000 claims 1
- PFUFMNONWYFELD-UHFFFAOYSA-N 4-[4-methyl-5-(1,2,3-trimethylindol-5-yl)-1,2,4-triazol-3-yl]phenol Chemical compound C=1C=C2N(C)C(C)=C(C)C2=CC=1C(N1C)=NN=C1C1=CC=C(O)C=C1 PFUFMNONWYFELD-UHFFFAOYSA-N 0.000 claims 1
- IGNNXZFHMSPANF-UHFFFAOYSA-N 4-[5-(2-chlorophenyl)-4-methyl-1,2,4-triazol-3-yl]-1-methylindole Chemical compound N=1N=C(C=2C=3C=CN(C)C=3C=CC=2)N(C)C=1C1=CC=CC=C1Cl IGNNXZFHMSPANF-UHFFFAOYSA-N 0.000 claims 1
- CKRIFUKNNIFAOQ-UHFFFAOYSA-N 4-methyl-3,5-bis[2-(trifluoromethyl)phenyl]-1,2,4-triazole Chemical compound CN1C(C=2C(=CC=CC=2)C(F)(F)F)=NN=C1C1=CC=CC=C1C(F)(F)F CKRIFUKNNIFAOQ-UHFFFAOYSA-N 0.000 claims 1
- KDVCRAPVYUBSJJ-UHFFFAOYSA-N 4-methyl-3-(2,4,6-trichloronaphthalen-1-yl)-5-[2-(trifluoromethyl)phenyl]-1,2,4-triazole Chemical compound N=1N=C(C=2C3=CC=C(Cl)C=C3C(Cl)=CC=2Cl)N(C)C=1C1=CC=CC=C1C(F)(F)F KDVCRAPVYUBSJJ-UHFFFAOYSA-N 0.000 claims 1
- BQCSQMTYTKDYHB-UHFFFAOYSA-N 4-methyl-3-(2-methylphenyl)-5-[2-(trifluoromethoxy)phenyl]-1,2,4-triazole Chemical compound CC1=CC=CC=C1C(N1C)=NN=C1C1=CC=CC=C1OC(F)(F)F BQCSQMTYTKDYHB-UHFFFAOYSA-N 0.000 claims 1
- NHCKUTVPDTXTNB-UHFFFAOYSA-N 4-methyl-3-(2-phenoxyphenyl)-5-[2-(trifluoromethyl)phenyl]-1,2,4-triazole Chemical compound CN1C(C=2C(=CC=CC=2)OC=2C=CC=CC=2)=NN=C1C1=CC=CC=C1C(F)(F)F NHCKUTVPDTXTNB-UHFFFAOYSA-N 0.000 claims 1
- VDAQBZPLWXZQHN-UHFFFAOYSA-N 4-methyl-3-(2-prop-2-ynoxyphenyl)-5-[2-(trifluoromethyl)phenyl]-1,2,4-triazole Chemical compound CN1C(C=2C(=CC=CC=2)OCC#C)=NN=C1C1=CC=CC=C1C(F)(F)F VDAQBZPLWXZQHN-UHFFFAOYSA-N 0.000 claims 1
- QPXIWXDWBDJNOR-UHFFFAOYSA-N 4-methyl-3-(4-pentylphenyl)-5-[2-(trifluoromethyl)phenyl]-1,2,4-triazole Chemical compound C1=CC(CCCCC)=CC=C1C(N1C)=NN=C1C1=CC=CC=C1C(F)(F)F QPXIWXDWBDJNOR-UHFFFAOYSA-N 0.000 claims 1
- DPCGGPAAWMXMJP-UHFFFAOYSA-N 4-methyl-3-[2-(trifluoromethoxy)phenyl]-5-[2-(trifluoromethyl)phenyl]-1,2,4-triazole Chemical compound CN1C(C=2C(=CC=CC=2)OC(F)(F)F)=NN=C1C1=CC=CC=C1C(F)(F)F DPCGGPAAWMXMJP-UHFFFAOYSA-N 0.000 claims 1
- GQDCUNTZBUHXEO-UHFFFAOYSA-N 4-methyl-3-[4-methylsulfanyl-2-(trifluoromethyl)phenyl]-5-[2-(trifluoromethyl)phenyl]-1,2,4-triazole Chemical compound FC(F)(F)C1=CC(SC)=CC=C1C(N1C)=NN=C1C1=CC=CC=C1C(F)(F)F GQDCUNTZBUHXEO-UHFFFAOYSA-N 0.000 claims 1
- 206010003210 Arteriosclerosis Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- WLYPBMBWKYALCG-UHFFFAOYSA-N [2,4-bis(trifluoromethyl)phenyl]boronic acid Chemical group OB(O)C1=CC=C(C(F)(F)F)C=C1C(F)(F)F WLYPBMBWKYALCG-UHFFFAOYSA-N 0.000 claims 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 125000005133 alkynyloxy group Chemical group 0.000 claims 1
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 1
- OUQNCJWPBUSXPR-UHFFFAOYSA-N chembl257963 Chemical compound N=1N=C(C=2C=3C=CN(C)C=3C=CC=2)N(C)C=1C1=CC=C(O)C=C1 OUQNCJWPBUSXPR-UHFFFAOYSA-N 0.000 claims 1
- 125000004367 cycloalkylaryl group Chemical group 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 claims 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims 1
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US55734404P | 2004-03-29 | 2004-03-29 | |
| PCT/US2005/009996 WO2005097759A1 (en) | 2004-03-29 | 2005-03-25 | Diaryltriazoles as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007530690A JP2007530690A (ja) | 2007-11-01 |
| JP2007530690A5 true JP2007530690A5 (enExample) | 2008-03-21 |
Family
ID=35124988
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007506284A Withdrawn JP2007530690A (ja) | 2004-03-29 | 2005-03-25 | １１−β−ヒドロキシステロイドデヒドロゲナーゼ−１の阻害剤としてのジアリールトリアゾール |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20080255216A1 (enExample) |
| EP (1) | EP1732904B1 (enExample) |
| JP (1) | JP2007530690A (enExample) |
| CN (1) | CN1938286A (enExample) |
| AU (1) | AU2005230864A1 (enExample) |
| CA (1) | CA2560314A1 (enExample) |
| WO (1) | WO2005097759A1 (enExample) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006105127A2 (en) | 2005-03-31 | 2006-10-05 | Takeda San Diego, Inc. | Hydroxysteroid dehydrogenase inhibitors |
| KR101081293B1 (ko) | 2006-01-18 | 2011-11-08 | 에프. 호프만-라 로슈 아게 | 11 베타-에이치에스디1 억제제로서 티아졸 |
| PE20080251A1 (es) | 2006-05-04 | 2008-04-25 | Boehringer Ingelheim Int | Usos de inhibidores de dpp iv |
| AU2007283113A1 (en) | 2006-08-08 | 2008-02-14 | Sanofi-Aventis | Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, processes for preparing them, medicaments comprising these compounds, and their use |
| WO2008039023A1 (en) * | 2006-09-29 | 2008-04-03 | Green Cross Corporation | Heteroaryl-pyrazole derivatives as cannabinoid cb1 receptor antagonists |
| EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| KR20100135711A (ko) | 2007-12-20 | 2010-12-27 | 엔비보 파마슈티칼즈, 인코퍼레이티드 | 사중치환된 벤젠 |
| SI2234985T1 (sl) * | 2007-12-20 | 2012-06-29 | Bayer Pharma AG | 4-(4-ciano-2-tioaril)dihidropirimidinoni in njihova uporaba |
| ES2714453T3 (es) * | 2008-06-09 | 2019-05-28 | Univ Muenchen Ludwig Maximilians | Fármacos para inhibir la agregación de proteínas implicadas en enfermedades relacionadas con enfermedades neurodegenerativas y/o agregación de proteínas |
| MX2011000179A (es) | 2008-07-03 | 2011-04-05 | Astellas Pharma Inc | Derivado de triazol o su sal. |
| US8470841B2 (en) | 2008-07-09 | 2013-06-25 | Sanofi | Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof |
| WO2010068601A1 (en) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof |
| JP2013503135A (ja) | 2009-08-26 | 2013-01-31 | サノフイ | 新規な結晶性複素芳香族フルオログリコシド水和物、その化合物を含んでなる医薬及びその使用 |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| EP2582709B1 (de) | 2010-06-18 | 2018-01-24 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| WO2012120056A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| EP2766349B1 (de) | 2011-03-08 | 2016-06-01 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| WO2012120058A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| EP2683699B1 (de) | 2011-03-08 | 2015-06-24 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| EP2683704B1 (de) | 2011-03-08 | 2014-12-17 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| EP2683703B1 (de) | 2011-03-08 | 2015-05-27 | Sanofi | Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| EP2683698B1 (de) | 2011-03-08 | 2017-10-04 | Sanofi | Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| US8809324B2 (en) | 2011-03-08 | 2014-08-19 | Sanofi | Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof |
| WO2012120054A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| EP3122740B1 (en) * | 2014-03-28 | 2019-09-18 | Syngenta Participations AG | Pesticidally active heterocyclic derivatives with sulphur containing substituents |
| US10548316B2 (en) | 2015-06-18 | 2020-02-04 | Nippon Soda Co., Ltd. | Diarylazole compound and harmful organism control agent |
| CN107849027B (zh) * | 2015-07-24 | 2021-03-12 | 先正达参股股份有限公司 | 具有含硫取代基的杀有害生物活性1,2,4-三唑衍生物 |
| US11136301B2 (en) * | 2015-08-31 | 2021-10-05 | The Regents of the University of California, A California Corporation et al. | Broad spectrum antiviral compounds and uses thereof |
| CN108026074A (zh) * | 2015-09-28 | 2018-05-11 | 先正达参股股份有限公司 | 具有含硫取代基的杀有害生物活性杂环衍生物 |
| EP3235813A1 (en) | 2016-04-19 | 2017-10-25 | Cidqo 2012, S.L. | Aza-tetra-cyclo derivatives |
| JP7472122B2 (ja) | 2018-11-20 | 2024-04-22 | スパロー ファーマシューティカルズ，インコーポレーテッド | コルチコステロイドを投与する方法 |
| CN119278039A (zh) | 2022-05-16 | 2025-01-07 | 麻雀制药股份有限公司 | 用于治疗糖皮质激素过量的方法和组合物 |
| GB202216323D0 (en) * | 2022-11-02 | 2022-12-14 | Cerevance Ltd | Novel compounds |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL7613137A (nl) * | 1975-11-26 | 1977-05-31 | Fisons Ltd | Werkwijzen voor de bereiding en toepassing van triazoliumverbindingen. |
| GB1571481A (en) | 1975-11-26 | 1980-07-16 | Fisons Ltd | 1,2,4-triazolium compounds having pesticidal and plant growth regulating properties |
| EP0036711B1 (en) * | 1980-03-22 | 1985-12-04 | Fbc Limited | Pesticidal heterocyclic compounds, processes for preparing them, compositions containing them, and their use |
| FR2692575B1 (fr) | 1992-06-23 | 1995-06-30 | Sanofi Elf | Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant. |
| US5292736A (en) | 1993-02-26 | 1994-03-08 | Sterling Winthrop Inc. | Morpholinoalkylindenes as antiglaucoma agents |
| JP3407088B2 (ja) * | 1994-06-27 | 2003-05-19 | イハラケミカル工業株式会社 | トリアゾール誘導体の製造方法およびその中間体 |
| US5532237A (en) | 1995-02-15 | 1996-07-02 | Merck Frosst Canada, Inc. | Indole derivatives with affinity for the cannabinoid receptor |
| FR2741621B1 (fr) | 1995-11-23 | 1998-02-13 | Sanofi Sa | Nouveaux derives de pyrazole, procede pour leur preparation et compositions pharmaceutiques en contenant |
| US5948777A (en) | 1997-03-18 | 1999-09-07 | Smithkline Beecham Corporation | Cannabinoid receptor agonists |
| KR20010021696A (ko) | 1997-07-11 | 2001-03-15 | 미즈노 마사루 | 퀴놀린 화합물 및 그의 의약용도 |
| EP1085869A4 (en) | 1998-06-11 | 2001-10-04 | Merck & Co Inc | Spiropiperidine derivatives as melanocortin receptor agonists |
| DE19837627A1 (de) | 1998-08-19 | 2000-02-24 | Bayer Ag | Neue Aminosäureester von Arylsulfonamiden und Analoga |
| JP2003505435A (ja) | 1999-06-04 | 2003-02-12 | メルク エンド カムパニー インコーポレーテッド | メラノコルチン−４受容体ゴニストとしての置換ピペリジン |
| TWI279402B (en) | 1999-08-20 | 2007-04-21 | Banyu Pharma Co Ltd | Spiro compounds having NPY antagonistic activities and agents containing the same |
| JP2003527444A (ja) | 2000-03-23 | 2003-09-16 | メルク エンド カムパニー インコーポレーテッド | メラノコルチン受容体アゴニストとして作用するスピロピペリジン誘導体 |
| US6458790B2 (en) | 2000-03-23 | 2002-10-01 | Merck & Co., Inc. | Substituted piperidines as melanocortin receptor agonists |
| MXPA03006918A (es) | 2001-02-02 | 2004-05-24 | Takeda Chemical Industries Ltd | Compuestos heterociclicos fusionados. |
| JP4104983B2 (ja) | 2001-02-28 | 2008-06-18 | メルク エンド カムパニー インコーポレーテッド | メラノコルチン−４受容体作動薬としてのアシル化ピペリジン誘導体 |
| SI1373216T1 (en) | 2001-03-22 | 2005-06-30 | Solvay Pharmaceuticals B.V. | 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity |
| US6573287B2 (en) | 2001-04-12 | 2003-06-03 | Bristo-Myers Squibb Company | 2,1-oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase IV and method |
| FR2824825B1 (fr) | 2001-05-15 | 2005-05-06 | Servier Lab | Nouveaux derives d'alpha-amino-acides, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| WO2003000180A2 (en) | 2001-06-20 | 2003-01-03 | Merck & Co., Inc. | Dipeptidyl peptidase inhibitors for the treatment of diabetes |
| US7253172B2 (en) | 2001-06-20 | 2007-08-07 | Merck & Co., Inc. | Dipeptidyl peptidase inhibitors for the treatment of diabetes |
| GB0115517D0 (en) | 2001-06-25 | 2001-08-15 | Ferring Bv | Novel antidiabetic agents |
| CN1990468A (zh) | 2001-06-27 | 2007-07-04 | 史密丝克莱恩比彻姆公司 | 作为二肽酶抑制剂的氟代吡咯烷 |
| ATE370943T1 (de) | 2001-06-27 | 2007-09-15 | Smithkline Beecham Corp | Fluoropyrrolidine als dipeptidyl-peptidase inhibitoren |
| CA2419888A1 (en) | 2001-06-27 | 2003-01-09 | Probiodrug Ag | Peptide structures useful for competitive modulation of dipeptidyl peptidase iv catalysis |
| JP4300108B2 (ja) | 2001-06-27 | 2009-07-22 | スミスクライン ビーチャム コーポレーション | ジペプチジルペプチダーゼ阻害剤としてのピロリジン類 |
| EP1404675B1 (en) | 2001-07-03 | 2008-03-12 | Novo Nordisk A/S | Dpp-iv-inhibiting purine derivatives for the treatment of diabetes |
| UA74912C2 (en) | 2001-07-06 | 2006-02-15 | Merck & Co Inc | Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes |
| AU2002319627A1 (en) | 2001-07-20 | 2003-03-03 | Merck And Co., Inc. | Substituted imidazoles as cannabinoid receptor modulators |
| US6977264B2 (en) | 2001-07-25 | 2005-12-20 | Amgen Inc. | Substituted piperidines and methods of use |
| EP1474139B1 (en) * | 2002-02-01 | 2007-11-21 | Merck & Co., Inc. | 11-beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia |
| AR040241A1 (es) | 2002-06-10 | 2005-03-23 | Merck & Co Inc | Inhibidores de la 11-beta-hidroxiesteroide deshidrogrenasa 1 para el tratamiento de la diabetes obesidad y dislipidemia |
-
2005
- 2005-03-25 CA CA002560314A patent/CA2560314A1/en not_active Abandoned
- 2005-03-25 WO PCT/US2005/009996 patent/WO2005097759A1/en not_active Ceased
- 2005-03-25 EP EP05726137.2A patent/EP1732904B1/en not_active Expired - Lifetime
- 2005-03-25 CN CNA2005800101374A patent/CN1938286A/zh active Pending
- 2005-03-25 US US10/593,010 patent/US20080255216A1/en not_active Abandoned
- 2005-03-25 JP JP2007506284A patent/JP2007530690A/ja not_active Withdrawn
- 2005-03-25 AU AU2005230864A patent/AU2005230864A1/en not_active Abandoned
-
2010
- 2010-04-14 US US12/759,737 patent/US8178546B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007530690A5 (enExample) | ||
| JP2010533158A5 (enExample) | ||
| JP2015533157A5 (enExample) | ||
| RU2352568C9 (ru) | [1,2,4]оксадиазолы (варианты), способ их получения, фармацевтическая композиция и способ ингибирования активации метаботропных глютаматных рецепторов-5 | |
| JP2018535999A5 (enExample) | ||
| JP2018507184A5 (enExample) | ||
| JP2020515575A5 (enExample) | ||
| JP2007523208A5 (enExample) | ||
| JP2019518036A5 (enExample) | ||
| RU2012116207A (ru) | Производные индола в качестве модуляторов crac | |
| JP2014511869A5 (enExample) | ||
| IL258577A (en) | 2,4-dihydroxy-nicotinamides as apj agonists | |
| RU2008141509A (ru) | Mglur5 модуляторы 1 | |
| JP2006503081A5 (enExample) | ||
| RU2006127575A (ru) | Соединение триазола и их применение в качестве антагонистов метаботропного рецептора глутамата | |
| JP2010504280A5 (enExample) | ||
| RU2006133909A (ru) | Производные азабицикло {3. 1. 0}гексана, применимые в качестве модуляторов допаминовых рецепторов d3 | |
| JP2019537603A5 (enExample) | ||
| JP2007523182A5 (enExample) | ||
| JP2014514299A5 (enExample) | ||
| JP2005536458A5 (enExample) | ||
| SI2513053T1 (en) | Pyrrolidine carboxylic acid derivatives as G-protein-coupled receptor 43 agonists (GPR43), pharmaceutical composition and methods for use in the treatment of metabolic disorders | |
| RU2011103789A (ru) | Производное триазола или его соль | |
| US20150150851A1 (en) | Formulation and dosing of hsp90 inhibitory compounds | |
| RU2008140940A (ru) | Производное триазола или его соль |